SNP array 检测胎儿心脏发育异常及本地区染色体变异热点
该研究纳入2021年1月至2024年12月因超声提示胎儿心脏发育软指标异常和(或)结构畸形而行SNP array检查的556例孕妇,分析不同超声表现和年龄分组的染色体变异检出情况。结果显示总染色体变异检出率为19.8%,致病性变异检出率为12.9%,致病性CNV以3q29、16p13.11、17p13.3p13.2、22q11.21区段最为多见。研究认为SNP array在产前诊断胎儿心脏发育异常中有重要应用价值。
要点
- 胎儿心脏发育异常行SNP array检查的总染色体变异检出率为19.8%,其中致病性变异占12.9%。
- 心脏结构畸形合并其他系统发育异常组染色体变异检出率最高,为10/16。
- 染色体非整倍体检出率随孕妇年龄增加而升高,≥40岁组检出率最高为16.7%。
核心结论
- SNP array技术在产前诊断胎儿心脏发育异常中有重要的应用价值。
- 研究本地区胎儿心脏发育异常相关染色体变异特点有利于先天性心脏病的精准治疗。
研究设计与样本
- 收集2021年1月至2024年12月于青岛大学附属烟台毓璜顶医院因超声提示胎儿心脏发育软指标异常和(或)结构畸形而行SNP array检查的孕妇556例。
- 根据超声结果分为软指标单项异常组237例、软指标多项异常组232例、软指标合并心脏结构畸形组24例、单独心脏结构畸形组47例、心脏结构畸形合并其他系统发育异常组16例。
- 根据孕妇年龄分为≤25岁组20例、26~29岁组155例、30~34岁组190例、35~39岁组149例、≥40岁组42例。
主要发现
- 共检出110例胎儿染色体变异,检出率为19.8%(110/556),其中致病性变异72例(12.9%,72/556),VUS 38例(6.8%,38/556)。
- 致病性CNV涉及9条染色体,以3q29、16p13.11、17p13.3p13.2、22q11.21区段最为多见。
- 心脏结构畸形合并其他系统发育异常组染色体变异检出率最高为10/16,软指标单项异常组为17.3%(41/237),软指标多项异常组为18.1%(42/232),软指标合并心脏结构畸形组为41.7%(10/24),单独心脏结构畸形组为14.9%(7/47),5组比较差异有统计学意义(χ2=27.680,P<0.001)。
- 染色体非整倍体检出率随年龄增加而升高,≥40岁组检出率为16.7%(7/42),最高。
- 致病性CNV、VUS、染色体异常总检出率在不同年龄分组间差异均无统计学意义(P均>0.05)。
关键数值与推荐
- 致病性CNV常见区段为3q29、16p13.11、17p13.3p13.2、22q11.21。
- 心脏结构畸形合并其他系统发育异常组检出率为10/16,软指标合并心脏结构畸形组检出率为41.7%(10/24)。
临床怎么用
- 对超声提示胎儿心脏发育软指标异常或结构畸形的孕妇,可行SNP array检查以评估染色体变异风险。
- 当胎儿同时存在心脏结构畸形和其他系统发育异常时,应高度重视染色体变异可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the application of single nucleotide polymorphism array (SNP array) in the detection of fetal cardiac dysplasia and to explore the characteristics of chromosomal variants associated with fetal cardiac dysplasia in the local population. Methods: A total of 556 pregnant women who underwent SNP array examination in Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University from January 2021 to December 2024 because of abnormal soft index or structural malformations of fetal heart development by ultrasound examination were collected. According to the results of fetal ultrasound examination, they were divided into single abnormal soft markers group (237 cases), multiple abnormal soft index group (232 cases), soft index combined with cardiac structural abnormalities group (24 cases), isolated cardiac structural abnormalities group (47 cases), and cardiac structural abnormalities combined with other systemic abnormalities group (16 cases). According to the age of pregnant women, they were divided into ≤25 years old group (20 cases), 26-29 years old group (155 cases), 30-34 years old group (190 cases), 35-39 years old group (149 cases) and ≥40 years old group (42 cases). The differences in the detection of chromosomal abnormalities in pregnant women with different echocardiographic results and different ages were compared. Results: (1) Among the 556 pregnant women who underwent SNP array for fetal cardiac anomalies, 110 cases of fetal chromosomal variations were detected, with a detection rate of 19.8% (110/556), including 72 cases of pathogenic variations (12.9%, 72/556) and 38 cases of variants of uncertain significance (VUS; 6.8%, 38/556). Pathogenic copy number variations (CNV) involved 9 chromosomes, with 3q29, 16p13.11, 17p13.3p13.2 and 22q11.21 being the most common. (2) Among the pregnant women with different ultrasound results, the highest detection rate of fetal chromosomal variation was in the group with cardiac structural abnormalities combined with other systemic abnormalities, with a detection rate of 10/16. The detection rates of single abnormal soft index group, multiple abnormal soft index group, soft index combined with cardiac structural abnormalities group and isolated cardiac structural abnormalities group were 17.3% (41/237), 18.1% (42/232), 41.7% (10/24) and 14.9% (7/47), respectively, and the differences were statistically significant (χ2=27.680, P<0.001). (3) In different age groups, the detection rate of chromosome aneuploidy increased with age, and the detection rate of ≥40 years old group (16.7%, 7/42) was the highest. There was no significant difference in the detection rate of pathogenic CNV, VUS and chromosomal abnormalities among different age groups (all P>0.05). Conclusions: SNP array technology has important application value in prenatal diagnosis of fetal cardiac anomalies. The study on the characteristics of chromosomal variants associated with fetal cardiac abnormalities in the local population is conducive to the precise treatment of congenital heart disease. 目的: 探讨单核苷酸多态性微阵列(SNP array)技术在心脏发育异常胎儿中的应用并探寻本地区胎儿心脏发育异常相关的染色体变异特点。 方法: 收集2021年1月至2024年12月于青岛大学附属烟台毓璜顶医院因超声检查提示胎儿心脏发育软指标异常和(或)结构畸形而行SNP array检查的孕妇556例。根据胎儿超声检查结果分为软指标单项异常组(237例)、软指标多项异常组(232例)、软指标合并心脏结构畸形组(24例)、单独心脏结构畸形组(47例)、心脏结构畸形合并其他系统发育异常组(16例);根据孕妇年龄分为≤25岁组(20例)、26~29岁组(155例)、30~34岁组(190例)、35~39岁组(149例)、≥40岁组(42例)。比较不同心脏超声检查结果、不同年龄分组的胎儿染色体异常检出的差异。 结果: (1)因胎儿心脏发育异常行SNP array检查的556例孕妇中,共检出110例胎儿染色体变异,检出率为19.8%(110/556),其中,致病性变异72例(12.9%,72/556),临床意义未明变异(VUS)38例(6.8%,38/556)。致病性拷贝数变异(CNV)涉及9条染色体,以3q29、16p13.11、17p13.3p13.2、22q11.21区段最为多见。(2)不同超声检查结果的孕妇中,胎儿染色体变异检出率最高者为心脏结构畸形合并其他系统发育异常组,检出率为10/16,软指标单项异常组、软指标多项异常组、软指标合并心脏结构畸形组、单独心脏结构畸形组的检出率分别为17.3%(41/237)、18.1%(42/232)、41.7%(10/24)、14.9%(7/47),5组比较,差异有统计学意义(χ2=27.680,P<0.001)。(3)不同年龄的孕妇中,染色体非整倍体检出率随年龄增加而升高,≥40岁组的检出率(16.7%,7/42)最高。致病性CNV、VUS、染色体异常的总检出率在不同年龄分组之间分别比较,差异均无统计学意义(P均>0.05)。 结论: SNP array技术在产前诊断胎儿心脏发育异常中有重要的应用价值。对本地区人群胎儿心脏发育异常相关染色体变异特点的研究有利于先天性心脏病的精准治疗。.
引用
- Ma, Yang, Liu, et al. [Detection of fetal cardiac dysgenesis by SNP array technology and the variation hotspots of the local population]. Zhonghua Fu Chan Ke Za Zhi. 2026. PMID: 41611265. doi:10.3760/cma.j.cn112141-20250627-00301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。